NCT06409507

Research and Application for New Clinical Diagnosis and Treatment System for HBV Related HCC Liver Transplantation

The Impact of FKBP12 on the Prognosis and Sirolimus Administration in Liver Transplantation Recipients With Hepatocellular Carcinoma: A Single-center Retrospective Cohort Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 178 (actual)
• Sponsor: First People's Hospital of Hangzhou · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: —

Summary

The study evaluated the protein expression levels of FK506-binding protein 12 (FKBP12) in hepatocellular carcinoma (HCC) and paracancerous tissues using immunohistochemistry (IHC). This study aimed to determine the role of FKBP12 in the outcome of liver transplantation recipients with HCC, especially those exceeding the Milan criteria. In addition, we explored how sirolimus administration affected LT recipients'prognosis depending on different FKBP12 expression, aiming to provide some advice for clinical sirolimus application after LT.

Conditions

• Hepatocellular Carcinoma
• Liver Transplantation
• Prognosis

Interventions

Type	Name	Description
GENETIC	FKBP12 expression	The expressions of FKBP12 were determined by immunohistochemistry (IHC) , and the immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels, and IRS (8-12) represented high expression levels.

Timeline

• Start date: 2015-01-01
• Primary completion: 2021-01-01
• Completion: 2023-08-01
• First posted: 2024-05-10
• Last updated: 2024-05-10